StockMacro
Menu

Prime Medicine

$3.55 +20% in 6 monthsMarket cap $791.6M

PRME on XNAS, Health Care, Prime Medicine, Inc., job postings

Measures activity, not value. Not investment advice.

Short interest sits at 16% of shares while free cash flow is -$158.5M and news runs 5.2 times its usual week.

  • WatchShares up 20% over six months but down 3.8% over twelve months
  • BadNet loss of $176.4M over twelve months; cash on hand $61.2M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
146
Website
primemedicine.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 2 Mar 2027 (an estimate: a year ago it reported on 3 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $4.2M, net loss $39.0M.
Quarter to 31 Dec 2021: revenue –, net income -$62.9MQuarter to 31 Mar 2022: revenue –, net income -$23.8MQuarter to 30 Jun 2022: revenue –, net income -$29.3MQuarter to 30 Sep 2022: revenue –, net income -$29.4MQuarter to 31 Dec 2022: revenue –, net income -$39.3MQuarter to 31 Mar 2023: revenue $0, net income -$39.4MQuarter to 31 Mar 2023: revenue $0, net income -$39.4MQuarter to 30 Jun 2023: revenue $0, net income -$42.4MQuarter to 30 Jun 2023: revenue $0, net income -$42.4MQuarter to 30 Sep 2023: revenue $0, net income -$50.7MQuarter to 30 Sep 2023: revenue $0, net income -$50.7MQuarter to 31 Dec 2023: revenue $0, net income -$65.6MQuarter to 31 Dec 2023: revenue $0, net income -$65.6MQuarter to 31 Mar 2024: revenue $591K, net income -$45.8MQuarter to 31 Mar 2024: revenue $591K, net income -$45.8MQuarter to 30 Jun 2024: revenue $0, net income -$55.3MQuarter to 30 Jun 2024: revenue $0, net income -$55.3MQuarter to 30 Sep 2024: revenue $209K, net income -$52.5MQuarter to 30 Sep 2024: revenue $209K, net income -$52.5MQuarter to 31 Dec 2024: revenue –, net income -$42.3MQuarter to 31 Mar 2025: revenue $1.5M, net income -$51.9MQuarter to 31 Mar 2025: revenue $1.5M, net income -$51.9MQuarter to 30 Jun 2025: revenue $1.1M, net income -$52.6MQuarter to 30 Jun 2025: revenue $1.1M, net income -$52.6MQuarter to 30 Sep 2025: revenue $1.2M, net income -$50.6MQuarter to 30 Sep 2025: revenue $1.2M, net income -$50.6MQuarter to 31 Dec 2025: revenue $838K, net income -$46.1MQuarter to 31 Dec 2025: revenue $838K, net income -$46.1MQuarter to 31 Mar 2026: revenue –, net income -$49.1MQuarter to 30 Jun 2026: revenue –, net income -$42.1MQuarter to 30 Sep 2026: revenue $4.2M, net income -$39.0MQuarter to 30 Sep 2026: revenue $4.2M, net income -$39.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $65.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$4.2M-$39.0M
30 Jun 2026–-$42.1M
31 Mar 2026–-$49.1M
31 Dec 2025$838K-$46.1M
30 Sep 2025$1.2M-$50.6M
30 Jun 2025$1.1M-$52.6M
31 Mar 2025$1.5M-$51.9M
31 Dec 2024–-$42.3M
30 Sep 2024$209K-$52.5M
30 Jun 2024$0-$55.3M
31 Mar 2024$591K-$45.8M
31 Dec 2023$0-$65.6M
30 Sep 2023$0-$50.7M
30 Jun 2023$0-$42.4M
31 Mar 2023$0-$39.4M
31 Dec 2022–-$39.3M
30 Sep 2022–-$29.4M
30 Jun 2022–-$29.3M
31 Mar 2022–-$23.8M
31 Dec 2021–-$62.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – $6.0M
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$176.4M -$197.3M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.98 -$1.44
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -207% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$158.5M -$115.1M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $61.2M $213.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$61.2M (net cash) -$213.3M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.05
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 76.5 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Prime MedicinePRME (this company) $791.6Mloss–––
MeiraGTxMGTX $779.9M10.01.9+1366%19.5%
Odyssey TherapeuticsODTX $815.2M––––
Monte Rosa TherapeuticsGLUE $738.3Mloss10.5-61%-186%
Aura BiosciencesAURA $715.0Mloss–––
Solid BiosciencesSLDB $697.6Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-0.5%

185 13F filers vs 186

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

68%

123.5M shares held by 13F filers (30 Sep 2026) of 181.9M outstanding (31 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

16%

29.1M shares sold short (30 Oct 2026) of 181.9M outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.8

29.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-11%

32.9M shares sold short in the report before, 29.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

37%

37% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 56%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

13

13 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.5×

13 articles in the last 7 days; its usual week has 2.

Price $3.55 on 20 Nov 2026, -3.8% over 12 months (12-month range $2.70 to $5.36)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $15.4M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 5 published in the last 12 months, -29% on the 12 months before.
Revenue per quarter. Revenue $4.2M in the latest quarter, +244% on a year earlier.
Capital spending per quarter. Capital spending $298K in the latest quarter, +21% on a year earlier.
Institutional holders (13F filers). 185 13F filers reported holding it in the latest 13F quarter, +18% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
16 Apr 20268-K and other filingsDirector or officer change
16 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Apr 2026Sharp changeShort interest spike: short interest spike, 30.0M vs usual 19.5M (2026-03-31); 1.6x the same period a year earlier
17 Mar 2026Sharp changeShort interest spike: short interest spike, 27.2M vs usual 19.2M (2026-02-27); 1.5x the same period a year earlier
3 Mar 2026Sharp changeShort interest spike: short interest spike, 28.1M vs usual 18.9M (2026-02-13); 1.6x the same period a year earlier
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 40 vs usual 23.50 (2025-12-31); 1.6x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 27.1M vs usual 18.5M (2026-01-30); 1.6x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 26.3M vs usual 18.4M (2026-01-15); 1.5x the same period a year earlier
13 Jan 2026Sharp changeShort interest spike: short interest spike, 25.7M vs usual 18.3M (2025-12-31); 1.5x the same period a year earlier
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 44 vs usual 21.50 (2025-09-30); 3.7x the same period a year earlier
5 Aug 20258-K and other filingsDirector or officer change
15 Jul 20258-K and other filingsDirector or officer change
23 May 2025Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 284K)
19 May 20258-K and other filingsDirector or officer change
19 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Jan 20248-K and other filingsDirector or officer change
5 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 May 20238-K and other filingsDirector or officer change
11 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Oct 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 34.0M)
17 Oct 20228-K and other filingsRegistered new securities for sale (S-1)
13 Oct 20228-K and other filingsRegistered new securities for sale (S-1)
23 Sep 20228-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Oct 2022: $34.0M published
Month from 1 May 2023: -$14.2M published
Month from 1 Jun 2023: -$5.8M published
Month from 1 Feb 2024: $20.0M published
Month from 1 May 2025: $284K published
Month from 1 Jun 2025: $110K published
Month from 1 Jul 2025: $53K published
Month from 1 Aug 2025: $14.9M published
H-1B/E-3 applications certified
Quarter from 1 Apr 2022: 1 published
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Oct 2022: 2 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Apr 2023: 2 published
Quarter from 1 Jul 2023: 7 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Jan 2024: 5 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2024: 3 published
Quarter from 1 Oct 2024: 2 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2025: 5 published
Quarter from 1 Oct 2025: 1 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Oct 2026: 3 published
Revenue per quarter
Quarter ended 31 Mar 2023: $0; public on 11 May 2024
Quarter ended 30 Jun 2023: $0; public on 9 Aug 2024
Quarter ended 30 Sep 2023: $0; public on 13 Nov 2024
Quarter ended 31 Dec 2023: $0; public on 1 Mar 2025
Quarter ended 31 Mar 2024: $591K; public on 11 May 2024
Quarter ended 30 Jun 2024: $0; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $209K; public on 13 Nov 2024
Quarter ended 31 Mar 2025: $1.5M, +146% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $1.1M; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $1.2M, +486% on a year earlier; public on 8 Nov 2025
Quarter ended 31 Dec 2025: $838K; public on 4 Mar 2026
Quarter ended 30 Sep 2026: $4.2M, +244% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $382K; public on 10 Mar 2023
Quarter ended 31 Mar 2022: $1.7M; public on 12 May 2023
Quarter ended 30 Jun 2022: $4.8M; public on 8 Aug 2023
Quarter ended 30 Sep 2022: $4.8M; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $4.8M, +1160% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $2.0M, +18% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $2.0M, -59% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $2.9M, -39% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $1.8M, -62% on a year earlier; public on 2 Mar 2024
Quarter ended 31 Mar 2024: $2.3M, +16% on a year earlier; public on 11 May 2024
Quarter ended 30 Jun 2024: $1.9M, -3.7% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $1.3M, -56% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $1.8M, -2.7% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $2.4M, +4.2% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $1.6M, -17% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $247K, -81% on a year earlier; public on 8 Nov 2025
Quarter ended 31 Dec 2025: $290K, -84% on a year earlier; public on 4 Mar 2026
Quarter ended 31 Mar 2026: $214K, -91% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $46K, -97% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $298K, +21% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2022 report: 61; public on 14 Feb 2023
31 Mar 2023 report: 75; public on 15 May 2023
30 Jun 2023 report: 73; public on 14 Aug 2023
30 Sep 2023 report: 77; public on 14 Nov 2023
31 Dec 2023 report: 99; public on 14 Feb 2024
31 Mar 2024 report: 109; public on 15 May 2024
30 Jun 2024 report: 115; public on 14 Aug 2024
30 Sep 2024 report: 113; public on 14 Nov 2024
31 Dec 2024 report: 128; public on 14 Feb 2025
31 Mar 2025 report: 121; public on 15 May 2025
30 Jun 2025 report: 117; public on 14 Aug 2025
30 Sep 2025 report: 157; public on 14 Nov 2025
31 Dec 2025 report: 173; public on 17 Feb 2026
31 Mar 2026 report: 184; public on 15 May 2026
30 Jun 2026 report: 186; public on 14 Aug 2026
30 Sep 2026 report: 185; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $5.0M (5 Aug 2025), 153× its normal reading; higher than 88% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $15.4M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 5 published in the last 12 months, -29% on the 12 months before.
  • Revenue per quarter: Revenue $4.2M in the latest quarter, +244% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 33 insider trades

No trades in the last 90 days; the latest was filed 5 Aug 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
5 Aug 2025Alphabet Inc. and 3 others10% ownerBuy1,500,000$3.30$5.0MForm 4
1 Aug 2025Steven Gillis and 7 others10% ownerBuy3,030,300$3.30$10.0MForm 4
1 Jul 2025David R. Liu10% ownerBuyplanned in advance (10b5-1)21,000$2.52$53KForm 4
23 Jun 2025David R. Liu10% ownerBuyplanned in advance (10b5-1)21,000$2.16$45KForm 4
16 Jun 2025David R. Liu10% ownerBuyplanned in advance (10b5-1)21,000$1.49$31KForm 4
12 Jun 2025David R. Liu10% ownerBuyplanned in advance (10b5-1)21,000$1.60$34KForm 4
22 May 2025Allan ReineChief Executive OfficerBuy125,000$1.18$148KForm 4
22 May 2025Richard BrudnickChief Business OfficerBuy20,000$1.19$24KForm 4

185 institutions reported shares at the end of Q3 2026, 68% of the shares outstanding; 23 opened a position, 23 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
ARCH Venture Management, LLC18.5M10.2%$56.5MNew+18.5M
Alphabet Inc.16.6M9.10%$50.7MNo change
BlackRock, Inc.10.7M5.89%$32.7M+1.1M+12%
ARK Investment Management LLC10.0M5.52%$30.7M+1.7M+20%
State Street Corp6.1M3.38%$18.8M-1.4M-19%
Vanguard Capital Management LLC4.6M2.52%$14.0M+57K+1.3%
T. Rowe Price Investment Management, Inc.4.6M2.50%-682K-13%
Balyasny Asset Management L.P.3.6M1.96%$10.9M-409K-10%
Casdin Capital, LLC3.2M1.74%$9.7MNo change
Woodline Partners LP3.0M1.65%$9.2M+4,293+0.1%

Company events

All 13 company events

In 12 months: 1 director or officer change, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
12 Nov 2026Underwriting agreement with Jefferies, TD Securities and Goldman Sachs for 35,714,286 shares at $3.50; net proceeds about $134.7M8-K
16 Apr 2026Director or officer change8-K
5 Aug 2025Director or officer changeSame filing: shareholder vote results8-K
31 Jul 2025Signed a major agreement8-K
15 Jul 2025Director or officer change8-K
19 May 2025Director or officer change8-K
30 Sep 2024Signed a major agreementSame filing: sold shares privately8-K
16 Feb 2024Signed a major agreement8-K

The 5 newest of 173 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Feb 2026confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Prime Medicine (PRME): saw 40 13F filers open a new position in the quarter ended 31 Dec 2025, 1.6× the same quarter last year, while it had 28.1M shares sold short in the 13 Feb 2026 report, 1.6× the same report last year. Two unrelated kinds of activity within 70 days.

  • Short interest and volume: Short interest spike, became public on 28 Jan 2026
  • Institutional holdings: Many funds opening a new position, became public on 17 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Feb 2026
  • Short interest and volume: Short interest spike, became public on 26 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Mar 2026
  • Short interest and volume: Short interest spike, became public on 11 Apr 2026
2023-12-31: 252024-03-31: 212024-06-30: 222024-09-30: 122024-12-31: 252025-03-31: 202025-06-30: 282025-09-30: 442025-12-31: 40
The quarter ended 31 Dec 2025 against the 8 quarters before it. this quarterearliernormal: 23.5
See the evidence (6 changes)

Short interest and volume: Short interest spike became public on 28 Jan 2026

Prime Medicine had 26.3M shares sold short in the 15 Jan 2026 report, 1.5× the same report last year.

This period
26.3M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
18.4M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+4.3
Same report last year
17.2M
History used
2,939 days
2025-01-15: 17.2M2025-01-31: 17.3M2025-02-14: 18.1M2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M
the 15 Jan 2026 report24 earlier reportsnormal: 18.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

Prime Medicine saw 40 13F filers open a new position in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.

This period
40 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
23.5
Typical spread (median absolute deviation)
3
How far from its usual level
+3.7
Same quarter last year
25
History used
1,096 days
2023-12-31: 252024-03-31: 212024-06-30: 222024-09-30: 122024-12-31: 252025-03-31: 202025-06-30: 282025-09-30: 442025-12-31: 40
the quarter ended 31 Dec 20258 earlier quartersnormal: 23.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 11 Feb 2026

Prime Medicine had 27.1M shares sold short in the 30 Jan 2026 report, 1.6× the same report last year.

This period
27.1M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
18.5M
Typical spread (median absolute deviation)
998K
How far from its usual level
+4.6
Same report last year
17.3M
History used
2,954 days
2025-01-31: 17.3M2025-02-14: 18.1M2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M
the 30 Jan 2026 report24 earlier reportsnormal: 18.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Feb 2026

Prime Medicine had 28.1M shares sold short in the 13 Feb 2026 report, 1.6× the same report last year.

This period
28.1M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
18.9M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+4.9
Same report last year
18.1M
History used
2,968 days
2025-02-14: 18.1M2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M2026-02-13: 28.1M
the 13 Feb 2026 report24 earlier reportsnormal: 18.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Mar 2026

Prime Medicine had 27.2M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year.

This period
27.2M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
19.2M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+4.2
Same report last year
18.0M
History used
2,982 days
2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M2026-02-13: 28.1M2026-02-27: 27.2M
the 27 Feb 2026 report24 earlier reportsnormal: 19.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Apr 2026

Prime Medicine had 30.0M shares sold short in the 31 Mar 2026 report, 1.6× the same report last year.

This period
30.0M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
19.5M
Typical spread (median absolute deviation)
2.0M
How far from its usual level
+3.6
Same report last year
18.3M
History used
3,014 days
2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M2026-02-13: 28.1M2026-02-27: 27.2M2026-03-13: 26.8M2026-03-31: 30.0M
the 31 Mar 2026 report24 earlier reportsnormal: 19.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 16 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 16 Apr 2026Filings record

    Director or officer change

  3. 11 Apr 2026Short interest and volume change

    had 30.0M shares sold short in the 31 Mar 2026 report, 1.6× the same report last year.

    Same report last year: 18.3M; its normal report is 19.5M.

    See the evidence
    This period
    30.0M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    19.5M
    Typical spread (median absolute deviation)
    2.0M
    How far from its usual level
    +3.6
    Same report last year
    18.3M
    History used
    3,014 days
    2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M2026-02-13: 28.1M2026-02-27: 27.2M2026-03-13: 26.8M2026-03-31: 30.0M
    the 31 Mar 2026 report24 earlier reportsnormal: 19.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 11 Mar 2026Short interest and volume change

    had 27.2M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year.

    Same report last year: 18.0M; its normal report is 19.2M.

    See the evidence
    This period
    27.2M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    19.2M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +4.2
    Same report last year
    18.0M
    History used
    2,982 days
    2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M2026-02-13: 28.1M2026-02-27: 27.2M
    the 27 Feb 2026 report24 earlier reportsnormal: 19.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 26 Feb 2026Short interest and volume change

    had 28.1M shares sold short in the 13 Feb 2026 report, 1.6× the same report last year.

    Same report last year: 18.1M; its normal report is 18.9M.

    See the evidence
    This period
    28.1M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    18.9M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +4.9
    Same report last year
    18.1M
    History used
    2,968 days
    2025-02-14: 18.1M2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M2026-02-13: 28.1M
    the 13 Feb 2026 report24 earlier reportsnormal: 18.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 17 Feb 2026several at once

    saw 40 13F filers open a new position in the quarter ended 31 Dec 2025, 1.6× the same quarter last year, while it had 28.1M shares sold short in the 13 Feb 2026 report, 1.6× the same report last year. Two unrelated kinds of activity within 70 days.

    See the evidence (6 changes)

    Short interest and volume: Short interest spike became public on 28 Jan 2026

    Prime Medicine had 26.3M shares sold short in the 15 Jan 2026 report, 1.5× the same report last year.

    This period
    26.3M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    18.4M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +4.3
    Same report last year
    17.2M
    History used
    2,939 days
    2025-01-15: 17.2M2025-01-31: 17.3M2025-02-14: 18.1M2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M
    the 15 Jan 2026 report24 earlier reportsnormal: 18.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

    Prime Medicine saw 40 13F filers open a new position in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.

    This period
    40 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    23.5
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +3.7
    Same quarter last year
    25
    History used
    1,096 days
    2023-12-31: 252024-03-31: 212024-06-30: 222024-09-30: 122024-12-31: 252025-03-31: 202025-06-30: 282025-09-30: 442025-12-31: 40
    the quarter ended 31 Dec 20258 earlier quartersnormal: 23.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 11 Feb 2026

    Prime Medicine had 27.1M shares sold short in the 30 Jan 2026 report, 1.6× the same report last year.

    This period
    27.1M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    18.5M
    Typical spread (median absolute deviation)
    998K
    How far from its usual level
    +4.6
    Same report last year
    17.3M
    History used
    2,954 days
    2025-01-31: 17.3M2025-02-14: 18.1M2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M
    the 30 Jan 2026 report24 earlier reportsnormal: 18.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Feb 2026

    Prime Medicine had 28.1M shares sold short in the 13 Feb 2026 report, 1.6× the same report last year.

    This period
    28.1M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    18.9M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +4.9
    Same report last year
    18.1M
    History used
    2,968 days
    2025-02-14: 18.1M2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M2026-02-13: 28.1M
    the 13 Feb 2026 report24 earlier reportsnormal: 18.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Mar 2026

    Prime Medicine had 27.2M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year.

    This period
    27.2M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    19.2M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +4.2
    Same report last year
    18.0M
    History used
    2,982 days
    2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M2026-02-13: 28.1M2026-02-27: 27.2M
    the 27 Feb 2026 report24 earlier reportsnormal: 19.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Apr 2026

    Prime Medicine had 30.0M shares sold short in the 31 Mar 2026 report, 1.6× the same report last year.

    This period
    30.0M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    19.5M
    Typical spread (median absolute deviation)
    2.0M
    How far from its usual level
    +3.6
    Same report last year
    18.3M
    History used
    3,014 days
    2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M2026-02-13: 28.1M2026-02-27: 27.2M2026-03-13: 26.8M2026-03-31: 30.0M
    the 31 Mar 2026 report24 earlier reportsnormal: 19.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  7. 17 Feb 2026Institutional holdings change

    saw 40 13F filers open a new position in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.

    Same quarter last year: 25; its normal quarter is 23.5.

    See the evidence
    This period
    40 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    23.5
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +3.7
    Same quarter last year
    25
    History used
    1,096 days
    2023-12-31: 252024-03-31: 212024-06-30: 222024-09-30: 122024-12-31: 252025-03-31: 202025-06-30: 282025-09-30: 442025-12-31: 40
    the quarter ended 31 Dec 20258 earlier quartersnormal: 23.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  8. 11 Feb 2026Short interest and volume change

    had 27.1M shares sold short in the 30 Jan 2026 report, 1.6× the same report last year.

    Same report last year: 17.3M; its normal report is 18.5M.

    See the evidence
    This period
    27.1M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    18.5M
    Typical spread (median absolute deviation)
    998K
    How far from its usual level
    +4.6
    Same report last year
    17.3M
    History used
    2,954 days
    2025-01-31: 17.3M2025-02-14: 18.1M2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M2026-01-30: 27.1M
    the 30 Jan 2026 report24 earlier reportsnormal: 18.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 28 Jan 2026Short interest and volume change

    had 26.3M shares sold short in the 15 Jan 2026 report, 1.5× the same report last year.

    Same report last year: 17.2M; its normal report is 18.4M.

    See the evidence
    This period
    26.3M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    18.4M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +4.3
    Same report last year
    17.2M
    History used
    2,939 days
    2025-01-15: 17.2M2025-01-31: 17.3M2025-02-14: 18.1M2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M2026-01-15: 26.3M
    the 15 Jan 2026 report24 earlier reportsnormal: 18.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 13 Jan 2026Short interest and volume change

    had 25.7M shares sold short in the 31 Dec 2025 report, 1.5× the same report last year.

    Same report last year: 16.9M; its normal report is 18.3M.

    See the evidence
    This period
    25.7M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    18.3M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +4.0
    Same report last year
    16.9M
    History used
    2,924 days
    2024-12-31: 16.9M2025-01-15: 17.2M2025-01-31: 17.3M2025-02-14: 18.1M2025-02-28: 18.0M2025-03-14: 19.4M2025-03-31: 18.3M2025-04-15: 16.7M2025-04-30: 16.5M2025-05-15: 17.7M2025-05-30: 18.0M2025-06-13: 18.5M2025-06-30: 20.1M2025-07-15: 21.7M2025-07-31: 21.9M2025-08-15: 18.4M2025-08-29: 19.2M2025-09-15: 19.1M2025-09-30: 20.0M2025-10-15: 15.8M2025-10-31: 18.2M2025-11-14: 18.6M2025-11-28: 19.7M2025-12-15: 21.9M2025-12-31: 25.7M
    the 31 Dec 2025 report24 earlier reportsnormal: 18.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 14 Nov 2025Institutional holdings change

    saw 44 13F filers open a new position in the quarter ended 30 Sep 2025, 3.7× the same quarter last year.

    Same quarter last year: 12; its normal quarter is 21.5.

    See the evidence
    This period
    44 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    21.5
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +4.3
    Same quarter last year
    12
    History used
    1,004 days
    2023-09-30: 82023-12-31: 252024-03-31: 212024-06-30: 222024-09-30: 122024-12-31: 252025-03-31: 202025-06-30: 282025-09-30: 44
    the quarter ended 30 Sep 20258 earlier quartersnormal: 21.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  12. 6 Aug 2025Insiders record

    Alphabet Inc. (ten percent owner) and 3 other(s) bought 1,500,000 shares of PRME ($5.0M) (dated 5 Aug 2025)

  13. 5 Aug 2025Filings record

    Director or officer change

  14. 2 Aug 2025Insiders record

    ARCH Venture Fund XII, L.P. (ten percent owner) and 2 other(s) bought 3,030,300 shares of PRME [same transaction as an earlier filing] (dated 1 Aug 2025)

  15. 2 Aug 2025Insiders record

    GILLIS STEVEN (ten percent owner) and 7 other(s) bought 3,030,300 shares of PRME ($10.0M) (dated 1 Aug 2025)

  16. 2 Aug 2025Insiders record

    NELSEN ROBERT (director) bought 3,030,300 shares of PRME [same transaction as an earlier filing] (dated 1 Aug 2025)

  17. 15 Jul 2025Filings record

    Director or officer change

  18. 2 Jul 2025Insiders record

    Liu David R. (ten percent owner) bought 21,000 shares of PRME ($52,920) (dated 1 Jul 2025)

  19. 24 Jun 2025Insiders record

    Liu David R. (ten percent owner) bought 21,000 shares of PRME ($45,360) (dated 23 Jun 2025)

  20. 17 Jun 2025Insiders record

    Liu David R. (ten percent owner) bought 21,000 shares of PRME ($31,290) (dated 16 Jun 2025)

  21. 13 Jun 2025Insiders record

    Liu David R. (ten percent owner) bought 21,000 shares of PRME ($33,600) (dated 12 Jun 2025)

  22. 23 May 2025Insiders change

    had 3 insiders buy $284K of its shares on the open market within 30 days (3 filings).

    Who bought: Lee Ann L., Brudnick Richard, Reine Allan.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $284K
    Window
    23 Apr 2025 to 23 May 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  23. 23 May 2025Insiders record

    Reine Allan (Chief Executive Officer) bought 125,000 shares of PRME ($147,500) (dated 22 May 2025)

  24. 23 May 2025Insiders record

    Brudnick Richard (Chief Business Officer) bought 20,000 shares of PRME ($23,800) (dated 22 May 2025)

  25. 23 May 2025Insiders record

    LEE ANN L. (Chief Technical Officer) bought 100,000 shares of PRME ($113,000) (dated 22 May 2025)

  26. 19 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 19 May 2025Filings record

    Director or officer change

  28. 21 Feb 2024Insiders record

    ARCH Venture Partners X, L.P. (ten percent owner) and 7 other(s) bought 3,200,000 shares of PRME ($20.0M) (dated 20 Feb 2024)

  29. 21 Feb 2024Insiders record

    NELSEN ROBERT (director) bought 3,200,000 shares of PRME [same transaction as an earlier filing] (dated 20 Feb 2024)

  30. 21 Feb 2024Insiders record

    ARCH Venture Partners XII, LLC (ten percent owner) and 2 other(s) bought 3,200,000 shares of PRME [same transaction as an earlier filing] (dated 20 Feb 2024)

  31. 5 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 5 Jan 2024Filings record

    Director or officer change

  33. 11 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 11 May 2023Filings record

    Director or officer change

  35. 27 Oct 2022Insiders change

    had 3 insiders buy $34.0M of its shares on the open market within 30 days (3 filings).

    Who bought: Nelsen Robert, Cahill Thomas.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $34.0M
    Window
    27 Sep 2022 to 27 Oct 2022

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  36. 27 Oct 2022Insiders record

    ARCH Venture Partners X, LLC (ten percent owner) and 7 other(s) bought 800,000 shares of PRME [same transaction as an earlier filing] (dated 26 Oct 2022)

  37. 27 Oct 2022Insiders record

    Cahill Thomas (director) bought 400,000 shares of PRME ($6.8M) (dated 26 Oct 2022)

  38. 27 Oct 2022Insiders record

    GV 2021, L.P. (Member of a 10% Group) and 6 other(s) bought 800,000 shares of PRME ($13.6M) (dated 26 Oct 2022)

  39. 27 Oct 2022Insiders record

    NELSEN ROBERT (director) bought 800,000 shares of PRME ($13.6M) (dated 26 Oct 2022)

  40. 17 Oct 2022Filings record

    Registered new securities for sale (S-1)

Showing the newest 40 of 42 entries; narrow the window or the kind of data to see older ones.

Not listed: 61 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001894562
Ticker
PRME
Domain
primemedicine.com
Employer name
Prime Medicine, Inc. (1 unverified)
Hq location
MA|CAMBRIDGE|02141 (1 unverified)
Name
Document, EX-21.1, fy202510-kex211.htm, Prime Medicine, Inc. and 1 more
Wikipedia
Prime Medicine
  • DOL H-1B labor condition applications and PERM certifications180 data points26 Oct 2020 to 14 Sep 2026
  • SEC Form 13F institutional holdings144 data points31 Dec 2022 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)55 records23 Sep 2022 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)333 data points31 Dec 2019 to 31 Oct 2026
  • SEC Form 4 insider transactions33 records, 96 data points26 Oct 2022 to 5 Aug 2025
  • FINRA short interest (twice monthly)400 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2202 data points13 Aug 2018 to 20 Nov 2026
  • Wikipedia pageviews10 data points11 Nov 2026 to 20 Nov 2026